Courier Capital LLC Reduces Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Courier Capital LLC cut its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 68.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,637 shares of the financial services provider’s stock after selling 5,700 shares during the period. Courier Capital LLC’s holdings in iShares Biotechnology ETF were worth $349,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Darwin Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF during the third quarter worth approximately $29,000. Highline Wealth Partners LLC purchased a new position in iShares Biotechnology ETF during the 3rd quarter worth $30,000. Ashton Thomas Securities LLC acquired a new position in iShares Biotechnology ETF in the third quarter valued at $36,000. Modus Advisors LLC acquired a new position in iShares Biotechnology ETF in the fourth quarter valued at $41,000. Finally, Voisard Asset Management Group Inc. purchased a new stake in shares of iShares Biotechnology ETF in the third quarter valued at about $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ IBB opened at $131.57 on Wednesday. iShares Biotechnology ETF has a 52-week low of $123.60 and a 52-week high of $150.57. The business’s 50-day moving average price is $137.78 and its 200 day moving average price is $141.97.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.